| Literature DB >> 35755817 |
Katya Ahmad1, Andrea Rizzi1,2, Riccardo Capelli3, Davide Mandelli1, Wenping Lyu4,5, Paolo Carloni1,6.
Abstract
The dissociation rate (k off) associated with ligand unbinding events from proteins is a parameter of fundamental importance in drug design. Here we review recent major advancements in molecular simulation methodologies for the prediction of k off. Next, we discuss the impact of the potential energy function models on the accuracy of calculated k off values. Finally, we provide a perspective from high-performance computing and machine learning which might help improve such predictions.Entities:
Keywords: QM/MM; drug discovery; enhanced sampling; kinetics; machine learning; molecular dynamics; parallel computing
Year: 2022 PMID: 35755817 PMCID: PMC9216551 DOI: 10.3389/fmolb.2022.899805
Source DB: PubMed Journal: Front Mol Biosci ISSN: 2296-889X
FIGURE 1Schematic of a LiGaMD Simulation. The LiGaMD potential (∆Uboost) acts when the potential energy of a protein-ligand complex (black line) is below a predefined threshold (dashed line), adding a harmonic potential to raise the energy of the system (cyan line) and favor the exploration of the conformational space of the ligand-protein complex.
FIGURE 2Schematic of a Metadynamics Simulation. On the CV-projected FES (red line), MetaD deposits a series of gaussians that sum up (from dark blue to white) until the system becomes diffusive in the CV space. This approach can be exploited to reduce the barrier height to have a reasonable transition time and reweight it a posteriori for an estimation of the kinetic constants (see Text).
FIGURE 3Simplified schematic depiction of the MSM construction pipeline. (A) Several continuous MD trajectories are simulated in parallel. (B) The trajectories are discretized. (C) A reversible transition probability matrix is calculated from a matrix of state-to-state transition counts (D) Probability fluxes between states (gray arrows, with line thickness representing the magnitude of the flux) indicate the highest likelihood transition paths and can be used to calculate the mean first passage time (MFPT) between states.
Quantitative in silico calculations (we highlighted in boldface the simulations that are below one order of magnitude for the predicted results with respect to the experimental ones)
| Target | Technique | T [K] | Force field |
|
| Simulation time [µs] | Ref | Year |
|---|---|---|---|---|---|---|---|---|
| Trypsin/Benzamidine | SEEKR | 298 | Amber14SB + GAFF | 83 ± 14 | 600 ± 300 | 19 | 10.1021/acs.jpcb.6b09388 | 2017 |
| Trypsin/Benzamidine | SEEKR | 298 | Amber14SB + GAFF | 174 ± 9 | 600 ± 300 | 4.4 | 10.1021/acs.jctc.0c00495 | 2020 |
| Trypsin/Benzamidine | SEEKR2 | 298 | Amber14SB + GAFF | 990 ± 70 | 600 ± 300 | 5 | 10.26434/chemrxiv-2021-pplfs | 2021 |
| Trypsin/Benzamidine | M-WEM | 298 | Amber14SB + GAFF | 791 ± 197 | 600 ± 300 | 0.48 | 10.1021/acs.jctc.1c00803 | 2022 |
| Trypsin/Benzamidine | Inf-MetaD | 300 | Amber99SB-ILDN | 9.1 ± 2.5 | 600 ± 300 | 5 | 10.1073/pnas.1424461112 | 2015 |
| Trypsin/Benzamidine | Inf-MetaD | 300 | Amber14SB + GAFF | 4176 ± 324 | 600 ± 300 | — | 10.1021/acs.jctc.8b00934 | 2019 |
| Trypsin/Benzamidine | MSM | 298 | Amber99SB + GAFF | (9.5 ± 3.3)·104 | 600 ± 300 | 50 | 10.1073/pnas.1103547108 | 2011 |
| Trypsin/Benzamidine | MSM | — | — | 2.8 ·104 | 600 ± 300 | 7.7 | 10.1021/ct400919u | 2014 |
| Trypsin/Benzamidine | MSM | — | Amber99SB + GAFF | 131 ± 109 | 600 ± 300 | 149.1 | 10.1038/ncomms8653 | 2015 |
| Trypsin/Benzamidine | MSM | 298 | Amber99SB + GAFF | 1170 [617, 2120] | 600 ± 300 | 58.28 | 10.1073/pnas.1525092113 | 2016 |
| Trypsin/Benzamidine | WExplore | 300 | Charmm36 + CGenFF | 5.56 ·104 | 600 ± 300 | 4.1 | 10.1016/j.bpj.2017.01.006 | 2017 |
| Trypsin/Benzamidine | REVO | 300 | Charmm36 + CGenFF | 2660 | 600 ± 300 | 8.75 | 10.1063/1.5100521 | 2019 |
| Trypsin/Benzamidine | LiGaMD | 300 | Amber14SB + GAFF | 3.53 ± 1.41 | 600 ± 300 | 5 | 10.1021/acs.jctc.0c00395 | 2020 |
| Trypsin/Benzamidine | dcTMD | 290 | Amber99SB* | 270 ± 40 | 600 ± 300 | 10000 | 10.1038/s41467-020-16655-1 | 2020 |
| Trypsin/Benzamidine | AMS | 298 | Charmm36 + CGenFF | 260 ± 240 | 600 ± 300 | 2.3 | 10.1021/acs.jctc.6b00277 | 2016 |
| Trypsin/Benzamidine | OPES | 300 | Amber14SB + GAFF | 687 | 600 ± 300 | 3.2 | arXiv:2204.05572 | 2022 |
| T4L L99A-Benzene | In-MetaD | 300 | Charmm22* | 6.0 ± 2.2 | 950 ± 200 | 6.7 | 10.1039/c7sc01627a | 2017 |
| T4L L99A-Benzene | FA-MetaD | 300 | Charmm22* | 5.7 ± 2.3 | 950 ± 200 | 5.5 | 10.1063/1.5024679 | 2018 |
| T4L L99A-Benzene | In-MetaD | 303 | Charmm36 | 270 ± 100 | 950 ± 200 | — | 10.1371/journal.pcbi.1006180 | 2018 |
| T4L L99A-Benzene | MSM | 303 | Charmm36 | 310 ± 130 | 950 ± 200 | 60 | 10.1371/journal.pcbi.1006180 | 2018 |
| T4L L99A-Indole | In-MetaD | 300 | Charmm22* + CGenFF | 9.8 ± 10.2 | 325 ± 75 | 4.5 | 10.1063/1.5024679 | 2018 |
| T4L L99A-Indole | FA-MetaD | 300 | Charmm22* + CGenFF | 6.0 ± 3.7 | 325 ± 75 | 2.0 | 10.1063/1.5024679 | 2018 |
| µOpioid receptor-morphine | In-MetaD | 300 | Charmm36 + CGenFF | (5.7 ± 0.5)·10–2 | (2.3 ± 0.2)·10–2 | 6 | 10.1063/5.0019100 | 2020 |
| µOpioid receptor-bruprenorphine | In-MetaD | 300 | Charmm36 + CGenFF | (2.1 ± 0.3)·10–2 | (1.8 ± 0.3)·10–3 | 19 | 10.1063/5.0019100 | 2020 |
| µOpioid receptor-Fentanyl | In-MetaD | 310 | Charmm36m + CGenFF | (2.6 ± 0.8)·10–2 (HID) (3.8 ± 1.4)·10–1 (HIE) 1.1 ± 0.3 (HIP) | 4.2 · 10–3 | 6 | 10.1021/jacsau.1c00341 | 2021 |
| TSPO-PK11195 | REVO | 300 | Charmm36 + CGenFF | (D1)6.4 · 10–5 (D2)6.67·101 (D3)6.4 · 10–3 (D4)4.1 · 10–3 (4RYI)6.0 · 10–4 (D1-D4 different docked poses) | 4.9 · 10–4 | 40 | 10.1016/j.bpj.2020.11.015 | 2021 |
| c-Src kinase-dasatinib | In-MetaD | 300 | OPLS | (4.8 ± 2.4)·10–2 | 5.6 · 10–2 1.1 · 10–3 | ∼7–8 | 10.1126/sciadv.1700014 | 2017 |
| Src kinase - imatinib | TS-PPTIS | 305 | Amber99SB*-ILDN + GAFF (QM/MM) | 0.026 | 0.11 ± 0.08 | — | 10.1021/acs.jctc.8b00687 | 2018 |
| Epoxide Hydrolase-TPPU | WExplore | 300 | Charmm36 + CGenFF | 2.4 · 10–2 [3.6 · 10–3 s−1, 4.4 · 10–2 s−1] | 1.5 · 10–3 | 6 | 10.1021/jacs.7b08572 | 2018 |
| p38 kinase/1-(3-(tert-butyl)-1- (p-tolyl)-1H-pyrazol-5-yl)urea | In-MetaD | 300 | Amber99SB-ILDN + GAFF | 0.020 ± 0.011 | 0.14 | 6.8 | 10.1021/jacs.6b12950 | 2017 |
| M2 muscarinic receptor/iperoxo | FA-MetaD | 310 | Amber14SB + GAFF | (3.7 ± 0.7)·10–4 | (1.0 ± 0.2)·10–2 | 8 | 10.1021/acs.jpclett.0c00999 | 2020 |
| HSP90-inhibitor | dcTMD | 300 | Amber99SB + GAFF | (1.6 ± 0.2)·10–3 | (3.4 ± 0.2)·10–2 | 5000 | 10.1038/s41467-020-16655-1 | 2020 |
| Mdm2/PMI | MSM | 300 | Amber99SB-ILDN | 0.125 [0.025, 0.66] 1.13 [0.48, 1.33] (Different rate matrix estimators) | 0.037 [0.029, 0.04] | 500 | 10.1038/s41467-017-01163-6 | 2017 |
| Mdm2/p53 | MSM | 300 | Amber99SB-ILDN-NMR | 1.9·105 | 2.1 | 831 | 10.1016/j.bpj.2017.07.009 | 2017 |
| SH3 Domain—1CKB | Pep-GaMD | 300 | Amber14SB | (1.45 ± 1.17)·10–3 | 8.9 · 10–3 | 3 | 10.1063/5.0021399 | 2020 |
| MtKatG—Isonazid | τRAMD + extrapolation | 300 | CHARMM36 + SwissParam | (2.8 ± 3.7)·10–2 | (2.0 ± 0.3)·10–2 | — | 10.1021/acs.jpclett.1c02952 | 2021 |
The Authors in the original work considered the experimental koff at 293 K (800 ± 200 s−1), while they simulated the system at 300 K. Here we choose to put the value at the closest temperature available in experiments (303K—950 ± 200 s−1). Both the experimental values come from (Feher et al., 1996).
The experimental value has been measured at 293 K.
For dcTMD, computational time is referred to 1D Langevin simulator, and the authors says that “1 ms of simulation time at a 5 fs time step take ∼6 h of wall-clock time on a single CPU”.